PROCEPT BioRobotics Corporation (PRCT)

NGM – Real Time Price. Currency in USD

22.56

+1.07 (4.98%)

At close: Jun 26, 2026, 4:00 PM EDT

21.64

-0.92 (-4.08%)

After-hours: Jun 26, 2026, 5:39 PM EDT

28.05.2026

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation® therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance.

14.05.2026

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), which strengthen the recommendation for Aquablation therapy (Robotic Waterjet Treatment) as a surgical treatment option for men with prostate volumes 30–80 mL.

13.05.2026

PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

30.04.2026

PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript

29.04.2026

PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.45 per share a year ago.

29.04.2026

PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026.

22.04.2026

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON PROCEPT BIOROBOTICS CORPORATION (PRCT) CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On Februa.

Videos

No Data

There is no data to display

Press releases

28.05.2026

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

14.05.2026

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

29.04.2026

PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

22.04.2026

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

PROCEPT BioRobotics Corporation (PRCT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

PROCEPT BioRobotics Corporation (PRCT)

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript

PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates

PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Videos

No Data

Press releases

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript

PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates

PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Videos

No Data

Press releases

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Search stocks

PROCEPT BioRobotics Corporation (PRCT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

PROCEPT BioRobotics Corporation (PRCT)

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript

PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates

PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Videos

No Data

Press releases

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript

PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates

PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Videos

No Data

Press releases

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm